Compare IFN & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IFN | KROS |
|---|---|---|
| Founded | 1993 | 2015 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 576.5M | 655.9M |
| IPO Year | N/A | 2020 |
| Metric | IFN | KROS |
|---|---|---|
| Price | $13.78 | $21.01 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $22.20 |
| AVG Volume (30 Days) | 135.2K | ★ 790.2K |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 8.68% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.57 |
| Revenue | N/A | ★ $246,718,000.00 |
| Revenue This Year | N/A | $6,924.79 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $13.35 |
| Revenue Growth | N/A | ★ 37798.31 |
| 52 Week Low | $14.40 | $9.12 |
| 52 Week High | $21.25 | $22.55 |
| Indicator | IFN | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 38.19 | 61.60 |
| Support Level | $13.46 | $19.76 |
| Resistance Level | $13.98 | $21.76 |
| Average True Range (ATR) | 0.16 | 0.82 |
| MACD | 0.05 | -0.12 |
| Stochastic Oscillator | 61.54 | 46.59 |
India Fund Inc is an asset management company. The fund's investment objective is long-term capital appreciation, which it seeks to achieve by investing in the equity securities of Indian companies. The company's portfolio is a non-diversified closed-end management investment company across various sectors such as financials, consumer staples, information technology, materials, healthcare, consumer discretionary, industrials, telecommunication services, utilities, and others. Geographically, all the business activity functions through the market of the United States.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.